Intravenous formulation and LC/MS/MS analysis method for GMC1
View Patent ↗Certain embodiments are directed to a GMC1 co-solvent formulation. The GMC1 co-solvent formulation described herein can be used for the treatment of prostate cancer, benign prostatic hypertrophy, and other hormone-related conditions involving androgen, glucocorticoid, and progesterone receptors.
1. A co-solvent formulation comprising (i) 20 to 80% PEG 300, (ii) 20 to 80% caprylocaproyl polyoxyl-8 glycerides and (iii) 1 to 200 mg/mL GMC1, wherein GMC1 has a formula of:
2. The co-solvent formulation of claim 1 , wherein the formulation comprises (i) 50% PEG 300, (ii) 50% caprylocaproyl polyoxyl-8 glycerides and (iii) 10 mg/mL GMC1.
3. A method of treating prostate cancer comprising administering to a subject having prostate cancer a formulation comprising (i) 20% to 80% PEG 300, (ii) 20% to 80% caprylocaproyl polyoxyl-8 glycerides and (iii) 1 to 200 mg/mL GMC1, wherein GMC1 has a formula of:
4. The method of claim 3 , further comprising administering chemotherapy or radiation treatments.